Avidity Biosciences is developing a new class of targeted RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). These AOCs combine monoclonal antibodies and oligonucleotides to deliver therapies to previously inaccessible tissues and target the underlying genetic drivers of diseases. The company is currently advancing programs for rare muscle diseases including myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy.